News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
265,064 Results
Type
Article (13728)
Company Profile (101)
Press Release (251235)
Section
Business (88112)
Career Advice (465)
Deals (15361)
Drug Delivery (66)
Drug Development (36650)
Employer Resources (49)
FDA (6295)
Job Trends (6200)
News (150355)
Policy (14034)
Tag
2024 BioCapital Digital (8)
2024 BioForest Digital (3)
2024 BioForest Standard (1)
2024 BioMidwest Digital (3)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (3)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (7)
2024 Biotech Beach Digital (4)
2024 Biotech Beach Standard (1)
2024 Genetown Digital (3)
2024 Genetown Standard (3)
2024 Lone Star Bio Digital (2)
2024 Pharm Country Digital (2)
2024 Pharm Country Standard (2)
2025 BioForest Digital (2)
2025 Lone Star Bio Digital (4)
2026 BioCapital Standard (1)
2026 Biotech Bay Standard (1)
2026 Pharm Country Standard (1)
Academia (440)
Adcomms (6)
Allergies (29)
Alliances (23220)
ALS (33)
Alzheimer's disease (384)
Antibody-drug conjugate (ADC) (34)
Approvals (6320)
Artificial intelligence (97)
Autoimmune disease (5)
Automation (3)
Bankruptcy (147)
Best Places to Work (4377)
BIOSECURE Act (9)
Biosimilars (52)
Biotechnology (40)
Bladder cancer (17)
Brain cancer (15)
Breast cancer (72)
Cancer (538)
Cardiovascular disease (60)
Career advice (406)
Career pathing (10)
CAR-T (17)
Cell therapy (76)
Cervical cancer (4)
Clinical research (30854)
Collaboration (302)
Compensation (126)
Complete response letters (16)
COVID-19 (759)
CRISPR (18)
C-suite (103)
Cystic fibrosis (35)
Data (550)
Denatured (15)
Depression (9)
Diabetes (73)
Diagnostics (1320)
Diversity (2)
Diversity, equity & inclusion (13)
Drug discovery (52)
Drug pricing (62)
Drug shortages (12)
Duchenne muscular dystrophy (27)
Earnings (31997)
Editorial (11)
Employer branding (4)
Employer resources (43)
Events (37478)
Executive appointments (331)
FDA (6642)
Featured Employer (20)
Friedreich's ataxia (2)
Funding (187)
Gene editing (34)
Generative AI (8)
Gene therapy (95)
GLP-1 (328)
Government (1284)
Grass and pollen (2)
Guidances (15)
Healthcare (3600)
Huntington's disease (4)
IgA nephropathy (8)
Immunology and inflammation (26)
Indications (11)
Infectious disease (790)
Inflammatory bowel disease (54)
Inflation Reduction Act (6)
Influenza (12)
Intellectual property (36)
Interviews (59)
IPO (5891)
IRA (29)
Job creations (2050)
Job search strategy (372)
Kidney cancer (6)
Labor market (7)
Layoffs (175)
Leadership (3)
Legal (3428)
Liver cancer (19)
Lung cancer (74)
Lymphoma (47)
Machine learning (1)
Management (16)
Manufacturing (133)
MASH (28)
Medical device (1274)
Medtech (1276)
Mergers & acquisitions (9631)
Metabolic disorders (232)
Multiple sclerosis (17)
NASH (14)
Neurodegenerative disease (19)
Neuropsychiatric disorders (5)
Neuroscience (540)
NextGen: Class of 2025 (1586)
Non-profit (594)
Northern California (645)
Now hiring (7)
Obesity (133)
Opinion (116)
Ovarian cancer (18)
Pain (46)
Pancreatic cancer (13)
Parkinson's disease (41)
Partnered (5)
Patents (93)
Patient recruitment (26)
Peanut (9)
People (28823)
Pharmaceutical (64)
Pharmacy benefit managers (11)
Phase I (8027)
Phase II (13054)
Phase III (11718)
Pipeline (324)
Podcasts (44)
Policy (56)
Postmarket research (1401)
Preclinical (3202)
Press Release (25)
Prostate cancer (41)
Psychedelics (8)
Radiopharmaceuticals (119)
Rare diseases (154)
Real estate (2633)
Recruiting (17)
Regulatory (10048)
Reports (13)
Research institute (563)
Resumes & cover letters (55)
Rett syndrome (1)
RNA editing (1)
RSV (6)
Schizophrenia (32)
Series A (33)
Series B (11)
Service/supplier (3)
Sickle cell disease (30)
Southern California (644)
Special edition (6)
Sponsored (6)
Startups (1628)
State (2)
Stomach cancer (3)
Supply chain (28)
The Weekly (28)
United States (6469)
Vaccines (144)
Venture capitalists (13)
Webinars (10)
Weight loss (91)
Women's health (8)
Worklife (3)
Date
Today (41)
Last 7 days (225)
Last 30 days (1105)
Last 365 days (12322)
2025 (2417)
2024 (12558)
2023 (14310)
2022 (19679)
2021 (20169)
2020 (19104)
2019 (14897)
2018 (11717)
2017 (13891)
2016 (13131)
2015 (15478)
2014 (12428)
2013 (10596)
2012 (11404)
2011 (11926)
2010 (10894)
Location
Africa (313)
Alabama (13)
Alaska (1)
Arizona (49)
Arkansas (3)
Asia (20086)
Australia (2598)
California (1553)
Canada (836)
China (197)
Colorado (63)
Connecticut (64)
Delaware (50)
Europe (39301)
Florida (281)
Georgia (34)
Idaho (9)
Illinois (169)
India (13)
Indiana (123)
Iowa (1)
Japan (79)
Kansas (54)
Kentucky (12)
Maine (2)
Maryland (236)
Massachusetts (1318)
Michigan (27)
Minnesota (83)
Missouri (22)
Montana (8)
Nebraska (6)
Nevada (7)
New Hampshire (6)
New Jersey (685)
New Mexico (7)
New York (447)
North Carolina (365)
North Dakota (2)
Northern California (645)
Ohio (44)
Oklahoma (4)
Oregon (16)
Pennsylvania (386)
Puerto Rico (5)
Rhode Island (6)
South America (500)
South Carolina (2)
Southern California (644)
Tennessee (31)
Texas (204)
Utah (32)
Virginia (67)
Washington D.C. (29)
Washington State (107)
Wisconsin (12)
265,064 Results for "nichi iko pharmaceutical".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Eisai and Nichi-Iko Enter into Collaboration Agreement for Generic Pharmaceutical Business in China
Eisai Co., Ltd. and Nichi-Iko Pharmaceutical have entered into a comprehensive collaboration agreement for the generic pharmaceutical business in China.
October 1, 2019
·
2 min read
Drug Development
Trust, Tech, and Tomorrow: A Pharmaceutical Executive’s WEF Insights
Konstantina Katcheves, Senior VP of Innovative Global Business Development at Teva Pharmaceuticals brings insights from the World Economic Forum to SCOPE 2025.
March 5, 2025
·
1 min read
·
Lori Ellis
BioMidwest
Sagent Pharmaceuticals Announces Start of NIAID-Sponsored Study Investigating COVID-19 Treatments in Outpatients
Sagent Pharmaceuticals, a Nichi-Iko Group Company, announced today that Camostat mesilate (Camostat), is one of four therapies being added to the existing ACTIV-2 Adaptive Platform Treatment Trial
February 12, 2021
·
3 min read
BioMidwest
Sagent Pharmaceuticals Announces FDA Acceptance of Omega Manufacturing Site
Nichi-Iko Pharmaceutical Co., Ltd. (“Nichi-Iko”) and Sagent Pharmaceuticals, Inc., a Nichi-Iko Group Company (“Sagent”), a leader of specialty pharmaceutical products with an emphasis on the injectable market, today announced that their Canadian subsidiary, Omega Laboratories Limited (“Omega”), has been found acceptable for manufacturing FDA-approved products in its initial Establishment Inspection Report issued by the U.S. FDA.
September 5, 2019
·
2 min read
Drug Development
COVID-19: Cytokine Storm and Coagulopathy Markers Controlled With Nichi Glucan Variants; The First of Its Kind Report in a Clinical Study
Cytokine storm and coagulopathy, the major life-threatening complications of COVID-19, whose biomarkers Interleukin-6 and D-Dimer were under control with consumption of two variants of Nichi Glucan food supplements from Japan in a pilot study.
October 12, 2021
·
3 min read
Drug Development
Sagent Pharmaceuticals Launches Phase 2 Trial to Evaluate Camostat Mesilate for COVID-19 Treatment
Sagent Pharmaceuticals, a Nichi-Iko Group Company, announced today that it has launched its Phase 2 CAMELOT trial to evaluate the safety and efficacy of Camostat Mesilate (Camostat) for the treatment of COVID-19 in high-risk outpatients and has begun enrolling patients
November 11, 2020
·
1 min read
Biotech Beach
ChromaDex to Launch Niagen+, the First-Of-Its-Kind Pharmaceutical-Grade Intravenous and Injectable Niagen® (Patented Nicotinamide Riboside Chloride or NRC)
ChromaDex Corp., the global authority on nicotinamide adenine dinucleotide research and its application to healthy aging, unveils Niagen+, the first-of-its-kind pharmaceutical-grade Niagen®.
June 13, 2024
·
9 min read
Press Releases
Avadel Pharmaceuticals to Present at Upcoming Investor Conferences
March 5, 2025
·
1 min read
Press Releases
Provectus Biopharmaceuticals Launches VisiRose, Provectus’s Founded Entity for Pharmaceutical-grade Rose Bengal Sodium-based Treatments in Ophthalmology
December 12, 2024
·
5 min read
Press Releases
Eledon Pharmaceuticals to Participate in Leerink Partners Global Healthcare Conference
March 4, 2025
·
1 min read
1 of 26,507
Next